Drug intelligence / Profile preview

New Tiaoxin Decoction

Development stage: Unknown
Lead developer: Shanghai Municipal Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

New Tiaoxin Decoction is a traditional Chinese medicine (TCM) herbal formulation developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine and Shanghai University of Traditional Chinese Medicine. It is primarily investigated for the treatment of mild cognitive impairment (MCI). As a decoction, it is a liquid preparation made by boiling herbal ingredients, intended to improve cognitive function and memory. In clinical trials, such as ChiCTR2000035938, it has been compared to the acetylcholinesterase inhibitor donepezil to evaluate its efficacy and safety in adults with MCI. The formulation is based on TCM principles of "regulating the heart" (Tiaoxin) to treat cognitive decline.

Other names: New Tiaoxin TangXin Tiaoxin Tang

Beyond the preview

Go deeper on New Tiaoxin Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Tiaoxin Decoction.

Explore the full profile